Nathan D. Seligson

Dabrafenib Versus Dabrafenib + Trametinib in <i>BRAF</i> -Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial

Naifa L. Busaidy, Bhavana Konda, Lai Wei et al. · Thyroid · 2022 · 106 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

<i>BRCA1/2</i> Functional Loss Defines a Targetable Subset in Leiomyosarcoma

Nathan D. Seligson, Esko A. Kautto, Edward N. Passen et al. · The Oncologist · 2018 · 77 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Degree of <i>MDM2</i> Amplification Affects Clinical Outcomes in Dedifferentiated Liposarcoma

Kate Lynn J. Bill, Nathan D. Seligson, John L. Hays et al. · The Oncologist · 2019 · 42 citations · Full text

Medicine, Oncology, Pathology +17

Common Secondary Genomic Variants Associated With Advanced Epithelioid Hemangioendothelioma

Nathan D. Seligson, Achal Awasthi, Sherri Z. Millis et al. · JAMA Network Open · 2019 · 34 citations · Full text

Medicine, Genetics, Oncology +16

Recommendations for patient similarity classes: results of the AMIA 2019 workshop on defining patient similarity

Nathan D. Seligson, Jeremy L. Warner, William S. Dalton et al. · Journal of the American Medical Informatics Association · 2020 · 28 citations · Full text

Medicine, Biomedical Informatics, Oncology +7